Article Text

Download PDFPDF
24 Exercise capacity improvement in adult congenital heart disease patients switching from bosentan to macitentan therapy
  1. S Herbert1,
  2. C Harries2,
  3. J Barbosa2,
  4. R Tulloh3,
  5. A Kempny2,
  6. C McCabe2,
  7. J Wort2,
  8. K Dimopoulos1,2,
  9. Laura Price1,2
  1. 1Joint Final Authors
  2. 2Royal Brompton and Harefield NHS Foundation Trust; London, UK
  3. 3Bristol Heart Institute; Bristol, UK


Purpose Therapeutic options for patients with congenital heart disease (PAH-CHD) are limited. Endothelin receptor antagonists do play a role,1 however the recent MAESTRO trial showed that Macitentan only improved six-minute walk distance (6 MWD) in the control group.2 We report real world use of patients who switch from Bosentan to Macitentan in a single centre PAH-CHD cohort.

Methods Clinical data was collected retrospectively from September 2014 to April 2017, up to 12 months after Macitentan introduction. Non-parametric statistical tests were used.

Results 16 PAH-CHD patients (13 female, age 52±10 years) were followed for 9.4 (0.7–25.9) months. All but 3 (19%) tolerated the change in medication, with no significant adverse events.

At three months, exercise capacity improved in the patients where paired 6 MW tests were available (n=6: mean 6 MW 261±159 m at baseline to 415±84 m at 3 months, p=0.05), but this was not maintained at later time points. There was no significant change in WHO FC. Oxygen saturations improved at 3 months (87±7 vs 91±8, p=0.3), but saturations post-exercise failed to improve. BNP fell at the 3 and 6 month assessment (from 223 to 163 ng/L, then to 181 ng/L at 6 months, p=0.4, p=0.7) but this was not sustained at 12 months (figure 1). Echocardiographic measurements including TAPSE showed a non-significant improvement from baseline to 6 to 9 months and a decline thereafter, in line with the BNP findings (figure 2).

Abstract 24 Figure 1 Graph demonstratingchanges in physiological parameters after Macitentan introduction at timepoints (0, 3, 6–9 and 12 months)

Abstract 24 Figure 2 Graph demonstratingchanges in echocardiographic parameters after Macitentanintroduction at time points (0, 3, 6–9 and 12 months)

Conclusion Exercise capacity, BNP and TAPSE improved after 3 months in some patients with PAH-CHD, but this was not sustained beyond 6 months.


  1. . Nazzareno G, Marc H, Jean-Luc V, Simon G, et al. 2015ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: The joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Eur Heart J 2016;37(1):67–119. doi:10.1093/eurheartj/ehv317

  2. . Galiè N. Actelion announces results of the MAESTRO study with Macitentan in patients with pulmonary arterial hypertension due to eisenmenger syndrome. [Accessed: May 2017].

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.